Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMQ95EB)

Drug Name
AS-601245 Drug Info
Synonyms
JNK Inhibitor V; SAPK Inhibitor V; 1,3-Benzothiazol-2-yl-(2-((2-(3-pyridinyl)ethyl)amino)-4-pyrimidinyl)acetonitrile; GTPL5997; SCHEMBL12242792; MolPort-044-724-552; HMS3229I20; CCG-206858; RT-013405; J-019673
Cross-matching ID
PubChem CID
10109823
ChEBI ID
CHEMBL406703
CAS Number
CAS 345987-15-7
TTD Drug ID
D04QCF

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
IL-17 signaling pathway 2.23 0.00e+0 84/94 (89.36%) MMP9;S100A8;S100A9;...
Staphylococcus aureus infection 2.21 0.00e+0 72/95 (75.79%) KRT14;KRT16;ITGB2;...
Collecting duct acid secretion 2.12 0.00e+0 22/27 (81.48%) CA2;ATP6V0E2;ATP6V0A1;...
Bile secretion 2.12 0.00e+0 68/90 (75.56%) CA2;ABCB1;ATP1B3;...
Rheumatoid arthritis 2.00 5.75e-3 78/93 (83.87%) CCL20;ATP6V0E2;TGFB1;...
VEGF signaling pathway 1.99 4.79e-3 50/59 (84.75%) MAPK1;MAP2K1;MAPKAPK3;...
Long-term depression 1.99 4.10e-3 55/60 (91.67%) GRIA2;MAPK1;GUCY1A1;...
Chemokine signaling pathway 1.98 3.59e-3 163/192 (84.9%) CCL20;MAPK1;LYN;...
Leishmaniasis 1.96 4.79e-3 67/77 (87.01%) TGFB1;MAPK1;FOS;...
Phagosome 1.92 8.62e-3 118/152 (77.63%) ATP6V0E2;CD14;ITGAV;...
Alcoholism 1.91 7.84e-3 86/186 (46.24%) MAPK1;MAP2K1;CALML5;...
Pancreatic secretion 1.91 7.18e-3 87/102 (85.29%) CA2;ATP1B3;RHOA;...
Hematopoietic cell lineage 1.91 6.63e-3 90/99 (90.91%) CD14;TFRC;ANPEP;...
Epithelial cell signaling in Helicobacter pylori infect... 1.89 8.21e-3 62/70 (88.57%) ATP6V0E2;LYN;PTPN11;...
Lysosome 1.87 7.66e-3 115/128 (89.84%) SLC11A2;SCARB2;LAPTM4B;...
Tuberculosis 1.87 7.18e-3 159/180 (88.33%) CD14;TGFB1;MAPK1;...
Asthma 1.87 6.76e-3 25/31 (80.65%) PRG2;FCER1G;HLA-DMB;...
Pertussis 1.86 6.39e-3 64/76 (84.21%) CD14;MAPK1;FOS;...
Long-term potentiation 1.86 6.05e-3 61/67 (91.04%) GRIA2;MAPK1;MAP2K1;...
Estrogen signaling pathway 1.84 7.90e-3 119/137 (86.86%) MMP9;KRT14;KRT16;...
PD-L1 expression and PD-1 checkpoint pathway in cancer 1.84 8.21e-3 79/89 (88.76%) MAPK1;FOS;MAP2K1;...
Gastric acid secretion 1.83 8.49e-3 63/76 (82.89%) CA2;SST;CALML5;...
Ascorbate and aldarate metabolism 1.81 8.75e-3 15/30 (50%) UGDH;UGT2A3;ALDH2;...
Chagas disease 1.80 9.58e-3 93/102 (91.18%) TGFB1;MAPK1;FOS;...
Neutrophil extracellular trap formation 1.79 9.19e-3 101/189 (53.44%) MAPK1;ITGB2;MAP2K1;...
Parathyroid hormone synthesis, secretion and action 1.79 9.95e-3 98/106 (92.45%) MAPK1;FOS;MAP2K1;...
Vibrio cholerae infection 1.79 9.58e-3 44/50 (88%) ATP6V0E2;ATP6V0B;KDELR1;...
Circadian entrainment 1.78 9.75e-3 85/97 (87.63%) GRIA2;MAPK1;GUCY1A1;...
Carbohydrate digestion and absorption 1.75 1.24e-2 37/47 (78.72%) ATP1B3;HK1;PRKCB;...
Colorectal cancer 1.74 1.44e-2 84/86 (97.67%) TGFB1;EREG;TGFA;...
Fanconi anemia pathway -1.85 4.30e-2 36/54 (66.67%) USP1;FANCA;MUS81;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone marrow
Chronic myeloid leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HAP1 CVCL_Y019 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 BRD4 (-) 1 CVCL_SF59 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 CDK4 (-) 1 CVCL_SI36 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 HDAC5 (-) 1 CVCL_SR11 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 ITGA4 (-) 1 CVCL_ST27 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 MAPK8 (-) 1 CVCL_SW99 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 PIK3CA (-) 1 CVCL_TD60 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 PRKACA (-) 1 CVCL_TG70 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 PRKCQ (-) CVCL_TG92 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 RELA (-) 1 CVCL_TI75 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 SRC (-) 1 CVCL_TQ36 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 TP53 (-) 1 CVCL_RJ70 Homo sapiens 0.66uM - 3.33uM 24H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.04uM - 10uM 3H, 6H, 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.04uM - 10uM 3H, 6H, 24H
SK-BR-3 CVCL_0033 Homo sapiens 0.04uM - 10uM 3H, 6H, 24H
Breast carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BT-20 CVCL_0178 Homo sapiens 0.04uM - 10uM 3H, 6H, 24H
Hs 578T CVCL_0332 Homo sapiens 0.04uM - 10uM 3H, 6H, 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.04uM - 10uM 3H, 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.04uM - 10uM 6H, 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.04uM - 10uM 6H, 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 0.04uM - 10uM 6H, 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.04uM - 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 0.04uM - 10uM 6H, 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.04uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.04uM - 10uM 6H, 24H